Lucid Diagnostics Inc. LUCD 深 沪
交易中 03-27 10:55:43 美东时间
1.105
-0.045
-3.91%
华盛通- 最 高1.49
- 今 开1.15
- 成交量 12.92万股
- 最 低 1.10
- 昨 收 1.15
- 总市值 4087.62万
- 52周最高 1.80
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 0.9495
- 委 比 -24.26%
- 总股本 3699.21万
- 历史最高 13.52
- 量 比 0
- 振 幅 33.91%
- 历史最低 0.6301
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
Why Is PAVmed Stock Skyrocketing Wednesday?
Pavmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for its cancer prevention test.
01-22 00:22
Lucid Diagnostics And Front Line Mobile Health Forge Partnership To Enhance Esophageal Cancer Screening Among First Responders
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of P...
2024-09-03 19:57
Lucid Diagnostics Announces Publication Of Analytical Validation Study Of EsoGuard For Early Detection Of Esophageal Precancer And Cancer In The Peer-Reviewed Journal Diagnostics
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the peer-reviewed publication of an analytical validation study of its EsoGuard® Esophageal DNA test for the ...
2024-08-20 20:18
